Palmitoyl Tetrapeptide-7
Tier 3 · Reported useThe strongest evidence present is a small (N=17), 1-month observational human cosmetic study of standalone Pal-GQPR, plus human data on the Matrixyl 3000 blend. However, most mechanistic support is in vitro (IL-6/IL-1β suppression in keratinocytes and fibroblasts) or proprietary expert opinion from the manufacturer (Sederma). Notably, several sources state Pal-GQPR has never been tested alone in a controlled human clinical trial, and essentially all robust positive results derive from the two-peptide Matrixyl 3000 blend containing Pal-GHK. Human evidence is therefore limited, small, and observational.
- Half-life
- Not recorded
- Routes
- Topical
- Goals
- longevity · immune support
- Cost / mg
- Not recorded
How it works
Palmitoyl tetrapeptide-7 is a lab-made peptide (the four amino acids Gly-Gln-Pro-Arg) attached to a fatty acid (palmitic acid). The fatty tail makes it more oil-loving so it can penetrate the skin's outer barrier and reach the deeper dermis. Its main reported action is calming chronic, low-grade inflammation in the skin by lowering the signaling molecule IL-6, which tends to rise with age and after UV exposure. By reducing this inflammatory signal, it is thought to help protect the skin's structural support (extracellular matrix) from breaking down. It is used almost exclusively as a topical anti-aging/skin-conditioning cosmetic ingredient, most famously as one of the two active peptides in the Matrixyl 3000 blend.
Overview
Overview
Palmitoyl Tetrapeptide-7 (also known as Pal-GQPR or Palmitoyl tetrapeptide-3) is a synthetic lipopeptide used almost exclusively as a topical cosmetic ingredient. It consists of the tetrapeptide Gly-Gln-Pro-Arg (GQPR) conjugated to palmitic acid (a 16-carbon fatty acid) at its N-terminus. The GQPR sequence is derived from residues 224–227 of immunoglobulin G (IgG), a domain associated with modulating immune responses.
The palmitoyl modification increases the peptide's lipophilicity, improving penetration through the stratum corneum to reach the dermis, and reduces the rate of proteolytic cleavage relative to the unmodified peptide. Applied topically (cream, gel, or lotion), it acts mainly locally in the skin, with little reaching the bloodstream.
Origin and Use
The ingredient was originally developed by Sederma SAS (around 2005) under the trade name Rigin, as an anti-inflammatory cosmeceutical targeting inflammaging. It functions primarily as a skin-conditioning agent in cosmetics. It is best known as one of the two active components of Matrixyl 3000, combined with palmitoyl tripeptide-1 (Pal-GHK) — in that blend, Pal-GQPR is described as suppressing the inflammatory environment driving matrix degradation while Pal-GHK stimulates collagen synthesis. As of 2018 it was reported to be the most frequently used peptide ingredient in anti-aging cosmetic products globally.
Reported Mechanism
The peptide's principal documented action is suppression of IL-6 secretion in keratinocytes and fibroblasts, addressing the chronic low-grade inflammation that accelerates skin aging. In vitro:
- Basal (constitutive) IL-6 secretion was reduced by up to ~40%.
- In UV-exposed cells, IL-6 was reduced by ~86% versus untreated UV-exposed controls (cell culture only, not demonstrated in human skin).
- Anti-inflammatory activity was reported comparable to DHEA (in vitro UV-cytokine reduction ~37% vs ~34%).
The peptide is designed to mimic DHEA activity and restore cytokine balance in mature skin, since DHEA declines with age and is associated with rising IL-6. By lowering IL-6, it is proposed to protect extracellular matrix components (with IL-6 suppression and MMP-1 inhibition as validated targets in skin-aging research). Additional expert/single-source claims include modulation of inflammaging and senescence-associated secretory phenotype, stimulation of laminin and nidogen at the dermal-epidermal junction, and stimulation of phagocytosis similar to Tuftsin. A PT-7 gel was also reported to reduce IL-1β and IL-6 induced by PM10 particulate-matter exposure, positioning it as a potential antipollution ingredient.
Clinical and Human Data
A standalone human study (N=17, 15 ppm, 1 month) reported a face firmness increase of 19%, neck firmness increase of 40%, elasticity improvement of 17% (face) and 27% (neck), deepest-wrinkle reduction of 56% at 15 days, and roughness reduction of 14%. The Matrixyl 3000 blend (Pal-GQPR + Pal-GHK) has been reported to exhibit noticeable anti-aging effects and to improve skin appearance and elasticity. Nanoliposomal co-delivery has been explored to enhance the bioactivity of anti-aging peptides in skin.
Chemistry
Reported molecular formula C34H62N8O7, molecular weight approximately 694.9 Da, CAS 221227-05-0, FDA UNII Q41S464P1R. (Note: sources disagree on the reported molecular weight, and one source uses a conflicting sequence designation — see caveats.)
What the research shows
24 findings extracted from the 7 sources cited below, strongest evidence first within each group. Every one links to the source it came from.
What human studies found
Based on 2 in vitro findings.
How it works
Based on 1 in vitro finding, 5 expert opinion findings and 1 theoretical finding.
in vitroNanodelivery systems can increase the safety and bioactivity of anti-aging peptides3
expert opinionPalmitoyl tetrapeptide-7 has peptide sequence Gly-Gln-Pro-Arg (GQPR)1
expert opinionThe Val-Gly-Val-Ala-Pro-Gly sequence is an elastin peptide1
expert opinionThe Gly-His-Lys sequence is a liver growth factor peptide and a fragment of type I collagen1
expert opinionPalmitoyl oligopeptides are related structurally by an identical fatty, hydrophobic tail connected to a variable sequence of peptides6
expert opinionSome small peptides are potent stimulators of angiogenesis6
theoreticalPeptides have considerable difficulty penetrating the stratum corneum due to high molecular weight, hydrophilic character, and susceptibility to enzymatic degradation3
Dosing
Based on 2 expert opinion findings.
Safety and side effects
Based on 1 animal finding, 2 in vitro findings and 5 expert opinion findings.
animalcosmetic composition is safe in both in vitro and in vivo studies4
in vitroPT-7 gel demonstrated safety2
in vitrocosmetic composition is stable4
expert opinionLow use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of Palmitoyl Tetrapeptide-7 in cosmetic products1
expert opinionLow use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of these ingredients in cosmetic products1
expert opinionThese ingredients are safe in the present practices of use and concentration in cosmetics1
expert opinionPalmitoyl tetrapeptide-7 is safe in the present practices of use and concentration6
expert opinionPalmitoyl oligopeptides data included chemistry (UV-visible spectral analysis, logP, and impurities data), methods of production, use concentration data, acute oral toxicity, ocular irritation, skin irritation/sensitization (animal and human), and genotoxicity6
What people use it for
Based on 3 in vitro findings and 2 expert opinion findings.
in vitroPT-7 is a promising antipollution cosmetic ingredient2
in vitroPalmitoyl tetrapeptide-7 (pal-KVK) can be co-delivered via nanoliposomes for anti-aging effects in skin3
in vitrocosmetic composition possesses preservative properties4
expert opinionPalmitoyl Tetrapeptide-7 functions primarily as a skin conditioning agent in cosmetics1
expert opinionTripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 function primarily as skin conditioning agents1
Points of contention
Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.
Contested
Sources disagree on the peptide's reported molecular weight
For the same compound (CAS 221227-05-0, sequence Pal-Gly-Gln-Pro-Arg), the reported molecular weight varies across references: ~694.9 Da (Palmitoyl Tetrapeptide-7 Dosing, Need to Know… | Peptide Initiative; Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace), ~594.78 g/mol (Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin): Research Evidence & Safety Profile | PeptideInsight), and ~687 Da (Palmitoyl Tetrapeptide-7: Evidence & Research | Peptidings). These are genuinely different figures for the same molecule.
Limited evidence
Mechanistic data is largely proprietary and in vitro, not confirmed in human skin
Palmitoyl Tetrapeptide-7: Evidence & Research | Peptidings notes the in vitro mechanism work is almost entirely proprietary (Sederma, the manufacturer) and independent peer-reviewed validation of GQPR's specific targets and binding behavior is minimal. Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace — PeptideTrace emphasizes IL-6 suppression has only been demonstrated in cell cultures, not in human skin.
Limited evidence
Standalone efficacy study is small, brief, and observational
The only cited standalone efficacy study (Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace — PeptideTrace) had N=17 subjects, ran for 1 month at 15 ppm, and is an observational cosmetic study rather than a controlled trial, limiting the strength of the firmness, elasticity, and wrinkle-reduction figures.
Single source
Claims about laminin/nidogen stimulation and inflammaging modulation come from a single source
The specific claims that Pal-GQPR stimulates laminin and nidogen production at the dermal-epidermal junction and modulates senescence-associated secretory phenotype are reported only by Palmitoyl Tetrapeptide-7 Dosing, Need to Know… | Peptide Initiative and are not corroborated by other sources.
Using it with other compounds
- PTD-DBMComplementary
No documented conflict
Palmitoyl Tetrapeptide-7 protects the extracellular matrix by damping inflammatory cytokines (IL-6, IL-1beta) and inhibiting MMP degradation, while PTD-DBM actively builds collagen/dermal matrix via Wnt/beta-catenin. One reduces breakdown while the other increases production, a complementary approach to skin quality.
Tier 4Theoretical — not establishedTiming Both topical cosmetic peptides.
Shares dermal matrix
- Palmitoyl Tripeptide-1Complementary
May be complementary
These two are the classic 'Matrixyl 3000' pairing in cosmetic formulations. Palmitoyl Tripeptide-1 (Pal-GHK) is a matrikine that actively drives fibroblasts to build new collagen, elastin and glycosaminoglycans, while Palmitoyl Tetrapeptide-7 works from the other direction — calming inflammatory cytokines (IL-6, IL-1β) and protecting the existing matrix from MMP-driven breakdown. Building plus protecting is exactly the kind of different-mechanism convergence that makes them a well-established, synergistic skin-firmness combination.
Tier 3Largely anecdotal — commonly discussedTiming Topical; apply together in the same routine.
Shares dermal matrix · anti inflammatory
- KPVComplementary
No documented conflict
Both reduce skin inflammation but at different points: palmitoyl tetrapeptide-7 suppresses IL-6/IL-1β in keratinocytes and fibroblasts, while KPV reduces keratinocyte apoptosis and inflammation (including from particulate matter) via NF-κB. In a topical anti-inflammaging context they address overlapping but distinct inflammatory signals.
Tier 4Theoretical — not establishedShares anti inflammatory
- LeuphasylComplementary
No documented conflict
Both are topical cosmetic peptides that improve skin appearance through different routes: Leuphasyl relaxes expression-line muscle signaling (and has reported minor matrix effects), while Palmitoyl Tetrapeptide-7 targets dermal-matrix protection and inflammation. Combining a wrinkle-relaxant with a matrix-protecting/anti-inflammatory peptide addresses distinct causes of aging skin.
Tier 4Theoretical — not establishedTiming Topical; no timing conflict.
Shares dermal matrix
- MatrixylComplementary
May be complementary
These two work as a classic cosmetic pair: Matrixyl actively builds new collagen and matrix, while Palmitoyl Tetrapeptide-7 calms inflammatory cytokines (IL-6, IL-1β) and protects the existing matrix from MMP-driven breakdown. One adds new material, the other prevents its degradation, so combining them addresses both sides of the collagen balance in aging skin.
Tier 3Largely anecdotal — commonly discussedTiming Topical use — designed to be co-formulated and applied together.
Shares dermal matrix
- ElafinComplementary
No documented conflict
Both protect the extracellular matrix and dampen inflammation, but by non-overlapping mechanisms — Elafin blocks destructive serine proteases (elastase, proteinase 3) and modulates NF-κB, whereas Palmitoyl Tetrapeptide-7 suppresses IL-6/IL-1β and inhibits MMP-1-driven collagen breakdown. Together they cover a broader range of matrix-degrading enzymes and inflammatory drivers.
Tier 4Theoretical — not establishedShares dermal matrix · anti inflammatory
- FOXO4-DRISame downstream effect
No documented conflict
Both act on the senescence-associated secretory phenotype (SASP)/inflammaging output, but differently: FOXO4-DRI reduces SASP by eliminating the senescent cells that produce it, while palmitoyl tetrapeptide-7 suppresses SASP-type inflammatory cytokines (IL-6, IL-1β) in skin cells. Converging on lower inflammatory secretion, though the tetrapeptide is a topical cosmetic acting locally.
Tier 4Theoretical — not establishedShares anti inflammatory
- GLOWComplementary
No documented conflict
Palmitoyl Tetrapeptide-7 is a topical anti-inflammatory peptide that suppresses IL-6/IL-1β and protects the matrix from MMP degradation ('inflammaging'). It complements GLOW's collagen-building and repair actions by calming the cytokine side of skin aging through a distinct route, making it a reasonable topical add-on for skin-quality goals.
Tier 4Theoretical — not establishedShares anti inflammatory · dermal matrix
- Alpha-MSHComplementary
No documented conflict
Alpha-MSH is anti-inflammatory in skin via NF-κB suppression (IκBα preservation), and Palmitoyl Tetrapeptide-7 achieves an overlapping outcome by lowering IL-6/IL-1β secretion. They converge on reduced cutaneous inflammation through different mechanisms; note that alpha-MSH also strongly drives pigmentation, which the tetrapeptide does not, so effects beyond inflammation are not shared.
Tier 4Theoretical — not establishedShares anti inflammatory
Safety and side effects
Safety and Side Effects
Safety reviews of palmitoyl oligopeptides (including palmitoyl tetrapeptide-7) concluded that the low use concentrations combined with negative safety test data obviate concerns, and that the ingredient is considered safe in the present practices of use and concentration in cosmetics.
The reviewed safety dataset for palmitoyl oligopeptides included:
- Chemistry (UV-visible spectral analysis, logP, impurities)
- Production methods and use-concentration data
- Acute oral toxicity
- Ocular irritation
- Skin irritation/sensitization (animal and human)
- Genotoxicity
A PT-7 gel demonstrated safety in in vitro testing, and cosmetic compositions containing the peptide were reported to be stable, safe in in vitro and in vivo studies, and to possess preservative properties.
Important Caveats
- Standalone human evidence is limited. Multiple sources note Pal-GQPR has essentially never been evaluated alone in a controlled human clinical trial; most robust positive results derive from the Matrixyl 3000 two-peptide blend with Pal-GHK, and it is unknown whether Pal-GQPR contributes meaningfully or is overshadowed by the better-studied Pal-GHK. The one cited standalone efficacy study is small (N=17), brief (1 month), and observational.
- Mechanism is largely proprietary and in vitro. The IL-6 suppression and related mechanistic work is largely from the manufacturer (Sederma) and cell-culture systems; IL-6 suppression has not been confirmed in human skin, and independent peer-reviewed validation is minimal.
- Single-source claims. Laminin/nidogen stimulation and SASP/inflammaging modulation are reported by only a single source.
- Data inconsistencies. Sources disagree on molecular weight (~694.9 Da, ~594.78 g/mol, ~687 Da for the same CAS number), and one source uses a conflicting sequence label ('pal-KVK') versus the widely reported GQPR sequence.
Reconstitution and handling
Preparation and Use
Palmitoyl tetrapeptide-7 is a topical cosmetic ingredient rather than an injectable/reconstituted peptide. It is formulated into leave-on products such as creams, gels, and lotions and acts mainly at the site of application, with little systemic absorption.
Typical Concentrations
- Typical/customary leave-on cosmetic use concentration of the active peptide is below 10 ppm (<0.001%).
- Cosmetic use concentrations in finished products typically range from 0.001% to 0.01%.
- In the cited standalone human study, the active was used at 15 ppm for 1 month.
- In manufacturer clinical testing, the trade-solution blend (Matrixyl 3000, ~3% concentration) was applied twice daily for about two months.
Application
Recommended application is to clean, dry skin, consistently at the same time daily, with evening application often preferred to allow overnight absorption. Peptides generally penetrate the stratum corneum poorly due to high molecular weight, hydrophilic character, and enzymatic degradation; the palmitoyl anchor improves penetration, and nanodelivery systems (e.g., nanoliposomes) have been explored to increase the safety and bioactivity of anti-aging peptides.
Sources
Ordered by evidence quality — the strongest first.
- Anti-aging peptides for advanced skincare: Focus on nanodelivery systems(opens in a new tab)Tier 2Web · sciencedirect.com
- Solid-phase synthesis of palmitoyl tetrapeptide-7. Adapted ...(opens in a new tab)Tier 2Web · researchgate.net
- Usage of Synthetic Peptides in Cosmetics for Sensitive Skin - PMC(opens in a new tab)Tier 2Web · pmc.ncbi.nlm.nih.gov
- Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts ...(opens in a new tab)Tier 3Web · cir-safety.org · 2014
See something wrong or out of date on this page? Report it.